CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells

Journal of Carcinogenesis

Volumn 11, Issue , 2012, Pages

  Sun, Yuan ^a,b   Luo, Dianzhong ^a   Liao, D ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Breast cancer; CDK4 6 kinase; chemosensitivity; cyclinD1; NF kB; TGF

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; FLUOROURACIL; GEMCITABINE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ARTICLE; BREAST CANCER; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

EID: 84872704288     PISSN: 09746773     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.100401     Document Type: Article

References (47)

1. Li Z, Wang C, Prendergast GC, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle 2006;5:2440-2. (Pubitemid 44785818)
2. Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L, et al. Cyclin D1 induction of cellular migration requires p27KIP1. Cancer Res 2006;66:9986-94. (Pubitemid 44672051)
3. Li Z, Wang C, Jiao X, Lu Y, Fu M, Quong AA, et al. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 2006;26:4240-56. (Pubitemid 43788023)
4. Zwijsen RM, Wientjens E, Klompmaker R, Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997;88:405-15. (Pubitemid 27131382)
5. Knudsen KE, Cavenee WK, Arden KC. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 1999;59:2297-301. (Pubitemid 29242271)
6. Inoue K, Sherr CJ. Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol 1998;18:1590-600. (Pubitemid 28100925)
7. Ratineau C, Petry MW, Mutoh H, Leiter AB. Cyclin D1 represses the basic helix-loop-helix transcription factor, BETA2/NeuroD. J Biol Chem 2002;277:8847-53. (Pubitemid 34952952)
8. Bienvenu Fdr, Gascan H, Coqueret O. Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism. J Biol Chem 2001;276:16840-7.
9. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003;114:323-34. (Pubitemid 36962931)
10. Han EK, Begemann M, Sgambato A, Soh JW, Doki Y, Xing WQ, et al. Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ 1996;7:699-710. (Pubitemid 26360738)
11. Sofer-Levi Y, Resnitzky D. Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E. Oncogene 1996;13:2431-7. (Pubitemid 27026026)
12. Pratt MA, Niu MY. Bcl-2 controls caspase activation following a p53-dependent cyclin D1-induced death signal. J Biol Chem 2003;278:14219-29.
13. Kuroda Y, Sakai A, Tsuyama N, Katayama Y, Munemasa S, Asaoku H, et al. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma. Int J Oncol 2008;33:1201-13.
14. Coco Martin JM, Balkenende A, Verschoor T, Lallemand F, Michalides R. Cyclin D1 overexpression enhances radiation-induced apoptosis and radiosensitivity in a breast tumor cell line. Cancer Res 1999;59:1134-40. (Pubitemid 29135977)
15. Niu MY, Menard M, Reed JC, Krajewski S, Pratt MA. Ectopic expression of cyclin D1 amplifies a retinoic acid-induced mitochondrial death pathway in breast cancer cells. Oncogene 2001;20:3506-18. (Pubitemid 32619403)
16. Zhou X, Zhang Z, Yang X, Chen W, Zhang P. Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity. Int J Cancer 2009;124:483-9.
17. Hochhauser D, Schnieders B, Ercikan-Abali E, Gorlick R, Muise-Helmericks R, Li WW, et al. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst 1996;88:1269-75. (Pubitemid 26301614)
18. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV, Korc M. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 1999;59:3505-11. (Pubitemid 29334515)
19. Kuhn DJ, Smith DM, Pross S, Whiteside TL, Dou QP. Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability. J Cell Biochem 2003;89:824-36. (Pubitemid 36759141)
20. Orr MS, Reinhold W, Yu L, Schreiber-Agus N, OConnor PM. An important role for the retinoblastoma protein in staurosporine-induced G1 arrest in murine embryonic fibroblasts. J Biol Chem 1998;273:3803-7. (Pubitemid 28103234)
21. Biliran H, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 2005;11:6075-86. (Pubitemid 41170340)
22. Shen KC, Miller F, Tait L, Santner SJ, Pauley R, Raz A, et al. Isolation and characterization of a breast progenitor epithelial cell line with robust DNA damage responses. Breast Cancer Res Treat 2006;98:357-64. (Pubitemid 44195607)
23. Sun Y, Li YX, Wu HJ, Wu SH, Wang YA, Luo DZ, et al. Effects of an indolocarbazole-derived CDK4 inhibitor on breast cancer cells. J Cancer 2011;2:36-51.
24. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994;91:709-13. (Pubitemid 24041471)
25. Fernandez RM, Ruiz-Miro M, Dolcet X, Aldea M, Gari E. Cyclin D1 interacts and collaborates with Ral GTPases enhancing cell detachment and motility. Oncogene 2011;30:1936-46.
26. Zhou Q, Wulfkuhle J, Ouatas T, Fukushima P, Stetler-Stevenson M, Miller FR, et al. Cyclin D1 overexpression in a model of human breast premalignancy: Preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity. Breast Cancer Res Treat 2000;59:27-39. (Pubitemid 30153895)
27. Sandler A, Ettinger DS. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 1999;4:241-51.
28. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261-8. (Pubitemid 29125078)
29. Ahnstrom M, Nordenskjold B, Rutqvist LE, Skoog L, Stal O. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Treat 2005;91:145-51. (Pubitemid 40684926)
30. Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, et al. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 2008;14:1767-74. (Pubitemid 351469462)
31. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO, Landberg G. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004;90:1942-8. (Pubitemid 38746334)
32. Xu J, Chen Y, Olopade OI. MYC and breast cancer. Genes Cancer 2010;1:629-40.
33. Hernndez-Vargas H, Rodrguez-Pinilla S, Julin-Tendero M, Snchez-Rovira P, Cuevas C, Antn A, et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 2007;102:157-72. (Pubitemid 46452170)
34. Zelivianski S, Cooley A, Kall R, Jeruss JS. Cyclin-dependent kinase 4-mediated phosphorylation inhibits Smad3 activity in cyclin d-overexpressing breast cancer cells. Mol Cancer Res 2010;8:1375-87.
35. Cooley A, Zelivianski S, Jeruss JS. Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines. Cell Cycle 2010;9:4900-7.
36. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H. Inhibition of NF-kB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 2002;73:237-43. (Pubitemid 34712997)
37. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. The NF-kB pathway and endocrine-resistant breast cancer. Endoc Relat Cancer 2005;12:S37-46. (Pubitemid 41398155)
38. Monks NR, Pardee AB. Targeting the NF-kappa B pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs. J Cell Biochem 2006;98:221-33.
39. Kwak YT, Li R, Becerra CR, Tripathy D, Frenkel EP, Verma UN. IkB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation. J Biol Chem 2005;280:33945-52. (Pubitemid 41443114)
40. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, et al. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci USA 2010;107:3698-703.
41. You Z, Madrid LV, Saims D, Sedivy J, Wang CY. c-Myc sensitizes cells to tumor necrosis factor-mediated apoptosis by inhibiting nuclear factor kB transactivation. J Biol Chem 2002;277:36671-7.
42. OHagan RC, Ohh M, David G, de Alboran IM, Alt FW, Kaelin WG Jr, et al. Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev 2000;14:2185-91.
43. Yeh PY, Lu YS, Ou DL, Cheng AL. IkappaB kinases increase Myc protein stability and enhance progression of breast cancer cells. Mol Cancer 2011;10:53.
44. Liu N, Fang H, Li Y, Xu W. Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment. Curr Med Chem 2009;16:4869-88.
45. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:558-72.
46. Sung B, Pandey MK, Aggarwal BB. Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-kB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkB alpha kinase activation. Mol Pharmacol 2007;71:1703-14. (Pubitemid 47010923)
47. Thoms HC, Dunlop MG, Stark LA. p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res 2007;67:1660-9. (Pubitemid 46383392)